New York, USA, Sept. 30, 2024 (GLOBE NEWSWIRE) -- KRAS Inhibitors Market: New Treatments Are Set to Change Cancer Care | DelveInsight According to DelveInsight’s analysis, the growth of the KRAS Inhibitors market is expected to be mainly driven by increasing incidence, a rise in awareness and access to treatment, and robust pipeline activity for cancer indications in the 7MM. DelveInsight’s KRAS Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging KRAS inhibitors, market share of individual therapies, and current and forecasted KRAS inhibitor market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the KRAS Inhibitor Market Report As per DelveInsight’s analysis, the total KRAS inhibitors market size in the 7MM was approximately USD 500 million in 2023, which is expected to rise significantly by 2034. Among the approved KRAS Inhibitor therapies in the United States, KRAZATI (adagrasib) is expected to have the edge over LUMAKRAS (sotorasib) in revenue generated during the study period (2020–2034). The United States had the highest number of KRAS mutation cases in NSCLC among the 7MM.
Approximately 46% of all KRAS mutation cases in NSCLC in the 7MM were reported in the United States. The competition in the G12C NSCLC segment is getting intense. A number of Chinese biotechs are also active in the KRAS Spac.
